Show simple item record

dc.contributor.authorRoudier, Emile
dc.contributor.authorLam, Brian
dc.date.accessioned2020-03-06T14:50:48Z
dc.date.available2020-03-06T14:50:48Z
dc.date.issued2019
dc.identifier.citationLam B and Roudier E (2019) Considering the Role of Murine Double Minute 2 in the Cardiovascular System? Front. Cell Dev. Biol. 7:320. doi: 10.3389/fcell.2019.00320en_US
dc.identifier.urihttps://doi.org/10.3389/fcell.2019.00320en_US
dc.identifier.urihttps://yorkspace.library.yorku.ca/xmlui/handle/10315/37064
dc.description.abstractThe E3 ubiquitin ligase Murine double minute 2 (MDM2) is the main negative regulator of the tumor protein p53 (TP53). Extensive studies over more than two decades have confirmed MDM2 oncogenic role through mechanisms both TP53-dependent and TP53-independent oncogenic function. These studies have contributed to designate MDM2 as a therapeutic target of choice for cancer treatment and the number of patents for MDM2 antagonists has increased immensely over the last years. However, the question of the physiological functions of MDM2 has not been fully resolved yet, particularly when expressed and regulated physiologically in healthy tissue. Cardiovascular complications are almost an inescapable side-effect of anti-cancer therapies. While several MDM2 antagonists are entering phase I, II and even III of clinical trials, this review proposes to bring awareness on the physiological role of MDM2 in the cardiovascular system.en_US
dc.description.sponsorshipYork University Librariesen_US
dc.language.isoenen_US
dc.publisherFrontiersen_US
dc.titleConsidering the role of Murine double minute 2 in the cardiovascular systemen_US
dc.typeArticleen_US
dc.rights.journalhttps://www.frontiersin.org/journals/cell-and-developmental-biologyen_US
dc.rights.publisherhttps://www.frontiersin.org/en_US
dc.rights.articlehttps://www.frontiersin.org/articles/10.3389/fcell.2019.00320/fullen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record